A double-blind, multicenter, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL 103 versus oral comparator in the treatment of community-acquired pneumonia in adults

Trial Profile

A double-blind, multicenter, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL 103 versus oral comparator in the treatment of community-acquired pneumonia in adults

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Amoxicillin; Linopristin/flopristin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Novexel
  • Most Recent Events

    • 12 Sep 2009 Results reported at ICAAC 2009.
    • 11 Sep 2009 Results will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Novexel media release.
    • 09 Jan 2009 Planned number of patients changed from 300 to 302, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top